Updates in oncology

Abstract

The objective of this review is to report the Clinical Year in Review proceedings in the field of thoracic oncology that were presented at the 2013 European Respiratory Society Annual Congress in Barcelona, Spain. Various topics were reviewed, including: epidemiology, screening, histology, and treatment of nonsmall cell lung cancer and small cell lung cancer. @ERSpublications Lung cancer increasing in females; screening based on risk selection; doublet platinum-based chemotherapy recommended http://ow.ly/sjbR6 EpidemiologyEuropean cancer mortality predictions for lung cancer in 2013 report a continuing reduction in males, but a continuing increase in females [1]. For the first time in females, mortality from lung and breast cancers should be equivalent. In 2013, age-standardised mortality rates per 100 000 are estimated to be 37.1 in males and 13.9 in females for lung cancer.A US epidemiological study [2] has confirmed the data of the UK doctors' cohort [3]. The authors obtained smoking and smoking-cessation histories from 113 752 females and 88 496 males who were interviewed between 1997 and 2004. These data were related to the causes of deaths that occurred by the end of 2006 (8236 deaths in females and 7479 in males). The rate of death from any cause among current smokers was approximately three times that among those who had never smoked. The hazard ratios for females and males were 3.0 (99% CI 2.7-3.3) and 2.8 (99% CI 2.4-3.1), respectively. Life expectancy was shortened by .10 years among the current smokers compared with those who had never smoked. Adults who had quit smoking 25-34, 35-44 or 45-54 years of age gained approximately 10, 9 and 6 years of life, respectively, compared with those who continued to smoke. This is in complete agreement with the UK observation.Temporal trends in mortality across three time-periods (1959-1965, 1982-1988 and 2000-2010) were compared in terms of absolute and relative risks according to sex and self-reported smoking status in two historical and five pooled contemporary US cohort studies [4]. For females who were current smokers compared with females who had never smoked, the relative risk of death from lung cancer was 2. 73, 12.65 and 25.66 in the 1960s, 1980s and contemporary cohorts, respectively; corresponding relative risk for male current smokers compared with males who had never smoked was 12.22, 23.81 and 24.97 over the same time-periods, respectively. As in Europe, the risk of death by lung cancer from cigarette smoking in the USA continues to increase among females and the increased risks are now nearly identical for males and females; however, this is not the case in Europe.By pooled analysis, the International Lung Cancer Consortium determined the associations between prior lung diseases and the occurrence of lung cancer [5]. The analysis included 17 studies with 24 607 cases and

Survival in surgical non-small cell lung cancer in a French Hospital

“…All our observations in this respect are consistent with the international literature. Indeed, adenocarcinoma was the most frequent histological type in our study, and its frequency increased from 1988 to 2011, from 34.1% to 38.8%, as previously observed in several reviews of the literature [20][21][22][23].…”

Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients

“…Non-small-cell lung cancer (NSCLC) is currently the most common type of lung cancer (1,2). Surgical resection remains the most consistent and successful treatment for NSCLC that has not spread beyond regional lymph nodes.…”

TheEuropean Respiratory Review: meeting expectations of respiratory physicians through diversity and quality

“…Four Clinical year in review articles were published in the March 2013 issue of the ERR [15][16][17][18] following the 2012 ERS Congress. In this issue of the ERR, four Clinical year in review articles [19][20][21][22] are published based on presentations from the 2013 ERS Congress in Barcelona, Spain, summarising the most important studies published in the 12 months prior to the ERS Congress.…”